ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC

ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC

User Photo
AnnualMeeting2017

3 years
938 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
Up Next Autoplay